Australian politicians and stakeholder representatives are cautiously optimistic about using psychedelics to treat mental health conditions, but hesitancy persists due to perceived inadequacy of research into efficacy and feasibility. Politicians consistently report that negative stigma prevents them and their peers from supporting psychedelic use. Effective, evidence-based messaging that refutes misconceptions and provides clear information is needed to improve knowledge and challenge attitudes, biases, and emotions influencing the debate. Both groups agree that insufficient evidence exists to support widespread clinical implementation in Australia, and additional research with clear presentation is required before clinical use can be supported.
Substance use disorder (SUD) is a chronic condition marked by maintained substance abuse leading to physiological and psychological changes, often altering cognitive and social behaviors. Current therapies combining psychotherapy and medication have high relapse rates, revealing their limitations. The serotonin 2C receptor (5-HT2C receptor) is a candidate for SUD treatment due to its signaling, expression profile, and neurological function. Recent interest in psychedelics, which broadly act at 5-HT2 receptors, has rekindled studies on the 5-HT2C receptor, especially structural analyses. This review examines the structural, molecular, and cellular mechanisms governing 5-HT2C receptor function in SUD, summarizing preclinical and clinical evidence and highlighting future research potential.